Charles Glover, MD
Cardiovascular Disease · Grand Junction, CONPI 1891955456
Payments from drug & device makers
What this record shows
Penumbra, Inc. accounts for 74.8% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $2,038, more than ten times the $24 reported in 2019.
Across 17 payments — averaging $154.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$2K
- Boston Scientific$231
- Shockwave Medical, Inc$225
- Edwards Lifesciences$155
- Abbott$24
- E.r. Squibb & Sons, L.L.C.$16
- plus $14 from 1 others
Across 1 payment — averaging $1827.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$2K
What the payments were for
- Travel & lodging$1,52058%
- Food & beverage$1,11142%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Penumbra, Inc. | 4 | $1,968 |
| Boston Scientific | 4 | $231 |
| Shockwave Medical, Inc | 3 | $225 |
| Edwards Lifesciences | 3 | $155 |
| Abbott | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Cardiva Medical, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,632 in reported general payments places this provider in the 55th percentile of 276 cardiovascular disease providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metoprolol Succinate | 18 | $147 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Grand Junction
- Payal KohliAurora$1.7M
- Marc BonacaAurora$703K
- Andrew FreemanDenver$454K
- William SauerAurora$365K
- Jeffrey BooneGreenwood Village$287K
- Rhonda MiyasakaAurora$128K
- Gregory SchwartzAurora$122K
- Deborah JalowiecColorado Springs$106K
- Edward GillAurora$96K
- Sameer MehtaDenver$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.